icon-folder.gif   Conference Reports for NATAP  
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 22-26 2022
Back grey_arrow_rt.gif
Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB)
  EASL 2022 June 22-26 London
E. Gane1, A Jucov2, L Kolomiichuk3, A Leerapun4, E Sripariwuth5, P Tangkijvanich6, SI Strasser7, T Suttichaimongkol8, C Cooper9, M Elkhashab10, Y-S Lim11, T Eley12, J Brown12, Y King12, T Varughese12, E Medvedeva12, M Chernyakhovskyy12, N Mani13, AG Cole13, S Kultgen13, R Pamulapati13, EP Thi13, T Harasym13, R Dugyala13, S Chaudhari13, M Sofia13, M Child12, G Picchio12, KD Sims12, MF Yuen14 1 Auckland Clinical Studies, New Zealand, 2 Arensia Exploratory Medicine, Moldova, 3 Arensia Exploratory Medicine, Ukraine, 4 Maharaj Nakhon Chiang Mai Hospital, Thailand, 5 Naresuan University Hospital, Thailand, 6 King Chulalongkorn Memorial Hospital, Thailand, 7 Royal Prince Alfred Hospital, Australia, 8 ACRO Khon Kaen University, Thailand, 9 Ottawa Hospital Research Institute, Canada, 10 Toronto Liver Centre, Canada, 11 Asan Institute for Life Science, South Korea, 12 Arbutus Biopharma Clinical Development, Warminster PA, USA, 13 Arbutus Biopharma Discovery and Research, Warminster, PA , USA 14 Queen Mary Hospital, Hong Kong